Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.42 |
| ▸ | FPR3 | P25089 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2690664 | 0.79 | FFAR2 (0.53) | FFAR2KDR | |
| SCHEMBL5216130 | 0.78 | MYC (0.44) | FFAR2 | |
| SCHEMBL2652269 | 0.77 | FFAR2 (0.57) | FFAR2 | |
| SCHEMBL5652094 | 0.76 | RAB9A (0.54) | — | |
| SCHEMBL2650712 | 0.76 | SMN1; SMN2 (0.54) | FFAR2FPR3FPR2 | |
| SCHEMBL30685441 | 0.75 | FFAR2 (0.50) | FFAR2KDR | |
| Ammonia Solution, Strong SCHEMBL27867504 | 0.74 | SMN1; SMN2 (0.52) | FFAR2FPR3FPR2 | |
| SCHEMBL15941111 | 0.73 | FFAR2 (0.45) | FFAR2 | |
| SCHEMBL1464407 | 0.72 | FFAR2 (0.60) | FFAR2 | |
| SCHEMBL10864137 | 0.72 | FFAR2 (0.40) | FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306116-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| EP-1931662-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | AstraZeneca AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031745-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306116-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | IGF1R, IGFBP1, IRS1 | FFAR2 1142/4885KDR 27/4885FPR3 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.